Protective Measures + Paralysis + Proning for Acute Respiratory Distress Syndrome

Recruiting in Palo Alto (17 mi)

+16 other locations

Overseen byKen K Parhar, MD, MSc

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Calgary

No Placebo Group

Trial Summary

What is the purpose of this trial?

Treatment of patients with Hypoxemic respiratory failure (HRF) and Acute Respiratory Distress Syndrome (ARDS) is complex. Therapies that have been shown to save the lives of patients with HRF and ARDS are available but they are not always provided. To reduce practice variation and improve adherence to evidence-informed therapies, the investigators developed the Treatment of Hypoxemic Respiratory Failure and ARDS with Protection, Paralysis, and Proning (TheraPPP) Pathway. The overall objective of TheraPPP Pathway is to improve the quality of care for patients with HRF. Implementation of the pathway across Alberta will test the effectiveness and implementation of the TheraPPP Pathway.

Research Team

Ken K Parhar, MD, MSc

Principal Investigator

University of Calgary

Eligibility Criteria

This trial is for patients in any of the 17 adult Intensive Care Units in Alberta who are on invasive mechanical ventilation due to severe respiratory issues like ARDS or hypoxemic respiratory failure. There are no specific exclusion criteria, so a wide range of patients with these conditions can participate.

Inclusion Criteria

Admitted to one of the 17 adult Intensive Care Units in Alberta

You are receiving help breathing with a machine.

Exclusion Criteria

It seems like there is no specific criterion provided in this case. If you need any further assistance, feel free to ask!

Treatment Details

Interventions

TheraPPP (Other)

Trial OverviewThe TheraPPP Pathway is being tested to see if it improves care for patients with acute respiratory problems. It involves evidence-based treatments including protection (lung-protective ventilation), paralysis (medication-induced), and proning (lying face down) to help breathing.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: TheraPPP PathwayExperimental Treatment1 Intervention

The investigators will perform an effectiveness-implementation hybrid study design (type 1) to evaluate the effectiveness and implementation of the TheraPPP pathway. All mechanically ventilated patients admitted to the ICU will enter the pathway. To evaluate effectiveness the investigators will collect patient data for approximately 29 months. To assess acceptability of the pathway the investigators will conduct a survey and focus groups to clinicians who used the Pathway.